We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Anemia is commonly observed among subjects with chronicrenalinsufficiency.
2
Background: Cardiovascular disorders are the leading cause of death in patients with chronicrenalinsufficiency.
3
These findings require confirmation by a large randomized trial conducted specifically in people with chronicrenalinsufficiency.
4
Several recently published reports have advanced our understanding of the epidemiology of anemia associated with chronicrenalinsufficiency.
5
Background: A potentially modifiable risk factor for cardiovascular disease in patients with mild chronicrenalinsufficiency is dyslipidemia.
6
This raises the concern that such diets might exacerbate the lipid problems already prevalent in chronicrenalinsufficiency.
7
Two control groups were formed by healthy volunteers (C) and non-diabetic subjects with chronicrenalinsufficiency (RI).
8
Cardiovascular disease is the main cause of death for patients with chronicrenalinsufficiency, particularly in patients with ESRD.
9
Objective: To determine whether pravastatin is effective and safe for secondary prevention of cardiovascular events in persons with chronicrenalinsufficiency.
10
The Reference Sheets list the most common nutrition-related concerns for chronicrenalinsufficiency, hemodialysis, peritoneal dialysis, and post kidney transplant patients.
11
We suggest that until better evidence becomes available, patients with chronicrenalinsufficiency should generally let their thirst guide fluid intake.
12
Conclusion: Sustained high urine volume and low Uosm are independent risk factors for faster GFR decline in patients with chronicrenalinsufficiency.
13
This study was conducted to determine whether pravastatin reduced rates of loss of renal function in people with moderate chronicrenalinsufficiency.
14
Limited data suggest that HMG-CoA reductase inhibitors (statins) may slow loss of renal function in individuals with chronicrenalinsufficiency.
15
Among those with chronicrenalinsufficiency or end-stage renal disease, detection of dyslipidemia requires more careful analysis and knowledge of normal pediatric ranges.
16
Since statins may be underused in this setting, physicians should consider prescribing them for patients with chronicrenalinsufficiency and known coronary disease.